Show simple item record

dc.contributor.authorElbuken, Filiz
dc.contributor.authorYildiz, Ibrahim
dc.contributor.authorKoksal, Ulkuhan I.
dc.contributor.authorTecimer, Coskun
dc.contributor.authorDemir, Gokhan
dc.contributor.authorOrdu, Cetin
dc.contributor.authorPilanci, Kezban N.
dc.contributor.authorAvci, Nilufer
dc.contributor.authorAlco, Gul
dc.contributor.authorDemirhan, Ozkan
dc.date.accessioned2021-03-05T18:08:03Z
dc.date.available2021-03-05T18:08:03Z
dc.date.issued2016
dc.identifier.citationOrdu C., Pilanci K. N. , Avci N., Yildiz I., Alco G., Demirhan O., Koksal U. I. , Elbuken F., Tecimer C., Demir G., "Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients", WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, cilt.20, ss.147-152, 2016
dc.identifier.othervv_1032021
dc.identifier.otherav_c8dd55b2-4ee8-4657-be15-3f92244ab7fc
dc.identifier.urihttp://hdl.handle.net/20.500.12627/133121
dc.identifier.urihttps://doi.org/10.5114/wo.2016.60069
dc.description.abstractAim of the study: Sunitinib-related side effects may develop as a result of the pharmacokinetic pathway affects the of the drug.
dc.language.isoeng
dc.subjectOnkoloji
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titlePrognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
dc.typeMakale
dc.relation.journalWSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY
dc.contributor.departmentİstanbul Bilim Üniversitesi , ,
dc.identifier.volume20
dc.identifier.issue2
dc.identifier.startpage147
dc.identifier.endpage152
dc.contributor.firstauthorID228740


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record